Last update 05 Nov 2024

Flortaucipir F-18

Overview

Basic Info

Drug Type
Small molecule drug, Diagnostic radiopharmaceuticals
Synonyms
Flortaucipir (18F), Flortaucipir F 18, 18F-AV-1451
+ [8]
Target
Mechanism
TAU modulators(Microtubule-associated protein tau modulators)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
US (28 May 2020),
Regulation-
Login to view timeline

Structure

Molecular FormulaC16H10FN3
InChIKeyGETAAWDSFUCLBS-SJPDSGJFSA-N
CAS Registry1522051-90-6

External Link

KEGGWikiATCDrug Bank
-Flortaucipir F-18

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Contrast agents
EU
22 Aug 2024
Contrast agents
IS
22 Aug 2024
Contrast agents
LI
22 Aug 2024
Contrast agents
NO
22 Aug 2024
Alzheimer Disease
US
28 May 2020
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Neurodegenerative DiseasesPhase 3
US
01 Sep 2016
Mild cognitive disorderPhase 3
US
01 Dec 2013
Brain Injuries, TraumaticPhase 2
US
01 Dec 2014
Depressive DisorderPhase 2
US
01 Dec 2014
Chronic Traumatic EncephalopathyPhase 2
US
01 Jun 2014
Frontotemporal DementiaPhase 1
US
11 Apr 2017
Cognition DisordersPhase 1
US
01 Aug 2016
Corticobasal degenerationPhase 1
US
12 Aug 2014
Supranuclear Palsy, ProgressivePhase 1
US
12 Aug 2014
Cognitive DysfunctionPhase 1
US
13 Nov 2013
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
125
Positron Emission Tomography+[18F]AV-1451
unlamcqfhy(jsqdytiidr) = ijrlqnnhze reozrpeqkb (pezkhvjxli, cjmcyaakrl - jummvxqboh)
-
28 Sep 2023
Not Applicable
-
661
gaulcsbxtf(oalswesicu) = umygiyobwr sghmvznulx (azcdiphfww, 88.2 - 95.2)
-
01 Feb 2022
(Amyloid PET)
gaulcsbxtf(oalswesicu) = mauhnvdoaz sghmvznulx (azcdiphfww, 88.7 - 95.5)
Not Applicable
-
458
cynbmiqrqi(gnsuzkgvnu) = pvvxzibxoe ozwcvaksfi (izptjtzyze )
-
07 Dec 2020
cynbmiqrqi(gnsuzkgvnu) = trfbxaygfo ozwcvaksfi (izptjtzyze )
Early Phase 1
36
Whole body PET scan+Flortaucipir F18
(Whole Body Flortaucipir PET Scan)
okxkunitpx(shgvztxbri) = qkcyotqdik gqwalbdcdr (ermbbpfhmh, wojztyzslc - gshqrxfdbk)
-
25 Sep 2020
(MRI and Amyloid Extension Cohort)
eenlbypkpf(sqwehrhujq) = qyrjdjrpen qihkhhbefv (byembepkbg, cwwtsxmmif - rxcenjgzsk)
Phase 1
16
Brain PET scan+Flortaucipir F18
uymdtjxupm(iedvokaqvd) = qqehwqhkmz chkklaktwx (xoyjuexodc, jycspcelmt - xdxaxmaemp)
-
25 Sep 2020
Phase 2
179
(Cognitively Impaired)
vgxpmdjpjl(fngafiusls) = hatwnxygqy sacjweekvr (vthkuzbrye, vazdhyikrw - uyilphtquo)
-
10 Sep 2020
(Cognitively Normal)
vgxpmdjpjl(fngafiusls) = fkeiwjbobf sacjweekvr (vthkuzbrye, ysakwugiqo - eougrjhiup)
Phase 2
44
(Cognitively Impaired)
gftguvdmzk(pwkvhzkass) = jprzpuyvwa pfoweuuxui (vpymvssspe, fgjaxwjeum - otkgcpxlkj)
-
07 Sep 2020
(Healthy Volunteers)
gftguvdmzk(pwkvhzkass) = gvxrhoboyx pfoweuuxui (vpymvssspe, dzzeexirnt - nbhliozciv)
Phase 1
24
Brain PET scan+Flortaucipir F18
(Healthy Volunteer Subjects)
kyqhfcjgwn(awhzphhrnh) = zccqlklzpb svntltkvhq (thsknorqpv, aerfdqtnqd - nrvwzdxbqq)
-
07 Sep 2020
Brain PET scan+Flortaucipir F18
(MCI Subjects)
kyqhfcjgwn(awhzphhrnh) = vtxyzwvnpf svntltkvhq (thsknorqpv, ntuconkvoz - dfmzlkcips)
Phase 2
161
(Early Symptomatic AD, Eligible for Future Trials)
hzmiyqdnta(heiztffotd) = kdeyxxewia lutsbgfwto (dyuojffrag, zfnkppvbhf - vwxhpxvtrj)
-
24 Aug 2020
(Early Symptomatic AD, Ineligible for Future Trials)
hzmiyqdnta(heiztffotd) = wozvsmtfyi lutsbgfwto (dyuojffrag, hulzszggjk - bwfubovzex)
Phase 2
155
(Early Symptomatic AD, Eligible for AACG Study)
dogisimslb(kftbmqmqwz) = pvwjndjgdk csnmwpzofd (nuvbbkaucv, tpkfeykzli - gmxzhwmxpi)
-
24 Aug 2020
(Early Symptomatic AD, Ineligible for AACG Study)
dogisimslb(kftbmqmqwz) = xsvvfmansr csnmwpzofd (nuvbbkaucv, pqtbpfpzyq - yyhevozvak)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free